BENTHAM SCIENCE MEDIA PARTNERSHIP FOR 3RD MIDDLE EAST INTERNATIONAL DERMATOLOGY & AESTHETIC MEDICINE CONFERENCE & EXHIBITIONS!

3RD MIDDLE EAST INTERNATIONAL DERMATOLOGY & AESTHETIC MEDICINE CONFERENCE & EXHIBITIONS

 

The conference aims to present to participants the latest developments in the fields of Dermatology and Aesthetics medicine, and share advance and innovative techniques & knowledge in Dermatology, Dermato-surgery & Aesthetics Medicine from around the world. This scientific conference intends to provide an evolving and unique forum for discussions and exchange among researchers and clinicians from all over the world as it facilitates the dissemination of the latest knowledge and expertise derived from research in the fields of Dermatology, Dermato-surgery and Aesthetics Medicine.

 

3rd Middle East International Dermatology ebook flyer

20% DISCOUNTS ON SUBSCRIPTIONS TO DELEGATES ATTENDING THE CONFERENCE ON EBOOKS FROM BENTHAM SCIENCE.

To avail, Qoute “BSPCNF18” at www.eurekaselect.com or email at marketing@benthamscience.org 

CONFERENCE WEBSITE: HTTPS://WWW.MEIDAMCONF.COM/

BENTHAM SCIENCE MEDIA PARTNERSHIP FOR 3rd Middle East International Dermatology & Aesthetic Medicine Conference & Exhibitions!

3rd Middle East International Dermatology & Aesthetic Medicine Conference & Exhibitions

 

The conference aims to present to participants the latest developments in the fields of Dermatology and Aesthetics medicine, and share advance and innovative techniques & knowledge in Dermatology, Dermato-surgery & Aesthetics Medicine from around the world. This scientific conference intends to provide an evolving and unique forum for discussions and exchange among researchers and clinicians from all over the world as it facilitates the dissemination of the latest knowledge and expertise derived from research in the fields of Dermatology, Dermato-surgery and Aesthetics Medicine.

 

3rd Middle East International Dermatology 3 journal flyers.jpg

20% DISCOUNTS ON SUBSCRIPTIONS TO DELEGATES ATTENDING THE CONFERENCE ON JOURNALS FROM BENTHAM SCIENCE.

 

To avail, Qoute “BSPCNF18” at www.eurekaselect.com or email at marketing@benthamscience.org 

 

Conference Website: https://www.meidamconf.com/

ARTICLE TO READ ON WORLD HEART DAY, 2018!

 

Hypertensive Heart Disease and the Role of Aldosterone Antagonists

 

Author(s): Chanwit Roongsritong, Ashwani Kumar, Leigh Ann Jenkins.

 

 

Abstract:

Hypertensive heart disease (HHD) encompasses a spectrum of abnormalities resulting from structural and functional adaptations to chronic pressure overload. The clinical manifestations of HHD range from asymptomatic left ventricular hypertrophy (LVH) to symptomatic heart failure. HHD has been associated with increased risk of cardiovascular morbidity and all cause mortality. However, regression of LVH by antihypertensive therapy has been associated with improved outcome. The pathogenesis of HHD involves various hemodynamic and nonhemodynamic factors including neurohormone, aldosterone. Aldosterone enhances myocardial fibrosis through its direct effect on mineralocorticoid and angiotensin II receptors leading to excessive collagen deposition within the myocardium. Increased myocardial fibrosis is a major determinant of hypertensive remodeling and the transition to heart failure. Aldosterone antagonists are effective antihypertensive agents. Additionally, they have been shown to improve LV structural remodeling, systolic and diastolic function in patients with HHD independent of its effect on blood pressure. Data on long-term benefit of these agents have thus far been limited to patients with advanced systolic heart failure and post-acute myocardial infarction LV systolic dysfunction. The potential benefit of aldosterone antagonists in patients with heart failure and preserved LV systolic function is currently being investigated in large scale clinical trials.

 

For more details, please visit: http://www.eurekaselect.com/59175

ARTICLE TO READ ON World Heart Day, 2018!

The Role of Myocardial Collagen Network in Hypertensive Heart Disease

 

Author(s): Javier Diez, Begona Lopez, Arantxa Gonzalez, Ramon Querejeta.

 

Abstract:

It is time to recognize that the quality, not quantity, of myocardium in hypertensive heart disease is responsible for adverse cardiovascular events. Experimental and clinical available data indicate that myocardial fibrosis due to the exaggerated accumulation of collagen type I and type III fibers predisposes to an enhanced risk of diastolic and/or systolic ventricular dysfunction, symptomatic heart failure, ischemic heart disease, and arrhythmia in patients with hypertensive heart disease. Thus, management of these patients must not only focus on detection and regression of left ventricular hypertrophy. Far more sensible are interventions aimed to detect and target hypertensive myocardial fibrosis. The available data on the use of biochemical and/or imaging methodologies to address excessive accumulation of collagen fibers in the myocardium of hypertensive patients are promising. On the other hand, preliminary data suggest that the goal of reducing myocardial fibrosis is achievable in patients with hypertensive heart disease treated with specific anti hypertensive agents. Collectively, these findings set the stage for larger trials where-in noninvasive measures and reparative strategies of myocardial fibrosis to prevent heart failure could prove useful.

 

For more details, please visit: http://www.eurekaselect.com/58592

World Heart Day, 2018!

 

 

world-heart-day-avial-discount-banner.jpg

 

World Heart Day is part of an international campaign to spread awareness about heart disease and stroke prevention. This is the perfect day to quit smoking, get exercising and start eating healthy – all in the name of keeping your ticker in good working order, and improving the health and well being of people the world over.

The World Heart Federation have found that heart disease and strokes are the world’s leading cause of death, killing 17.1 million people every year – that’s more than victims of cancer, HIV and AIDS and malaria.

 

Bentham Science publishes articles related to World Heart Day in its Subscription based journals including:

To Avail 20% Discount on related eBooks, kindly visit: https://ebooks.benthamscience.com/

ARTICLE BY DISEASE – Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer

ARTICLE BY DISEASE ON “ADRENOCORTICAL CANCER”

 

Adrenocortical carcinoma (ACC) is a rare neoplasm with very poor prognosis despite the recent development of aggressive antitumor therapies. The cause of adrenal cancer remains elusive, but some molecular mechanisms could be responsible for its development. Target-specific therapies have been developed for a number of human malignancies and have resulted in therapeutic benefits in some cancer patients. However, these therapies are only effective in cases in which the corresponding targets are expressed in tumor tissues. Molecular analysis has had a significant impact on the understanding of the pathogenetic mechanism of ACC development and the evaluation of prognostic and predictive markers, among which alterations of the IGF system, the Wnt pathway, p53 and molecules involved in cancer cell invasion properties and angiogenesis seem to be very promising. These molecular markers may not just play a role in the biology of these tumors and have prognostic implications, but can also be used as potential targets for treatment. The aim of this review is to summarize the genetic and molecular events implied in the pathogenesis of ACC and to highlight challenges to the development of anticancer agents in recent patents.

 

For more details, please visit: http://www.eurekaselect.com/node/89180/article

ARTICLE BY DISEASE – The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients

 

ARTICLE BY DISEASE ON “ACOUSTIC NEUROMA”

 

Background: Inflammation is known to play a role in cererovascular risk. Multiple sclerosis (MS) is a neurodegenerative disease that is initially characterized by inflammatory changes in the brain. We hypothesized that due to chronic inflammation, MS patients would present with a higher levels of cardiovascular (CV) risk factors than non-MS patients.

Methods: We performed a retrospective chart review on 206 MS patients and 142 control patients suffering from meningiomas and acoustic neuromas, non inflammatory, non autoimmune diseases of the brain. The obtained data included fasting lipid profiles, plasma glucose, systolic and diastolic blood pressure (BP), serum levels of homocysteine and uric acid, data on iron status, smoking habit, and list of medications. In addition, data on indicators of MS disease severity was obtained for MS patients.

Results: MS patients had significantly higher total plasma cholesterol, p = 0.01, and plasma high density lipoprotein, P <0.001, but lower plasma glucose, P <0.001, and systolic BP, P = 0.001, than non-MS patients. In addition, MS patients had lower erythrocyte sedimentation rate and serum vitamin B12, but higher serum folic acid and vitamin D3 than non-MS patients. A positive correlation was observed between plasma glucose and the extended disability status scale (EDSS), P = 0.008, and between plasma glucose and the rate of clinical relapse, P = 0.001.

Conclusion: The MS pathophysiology may be among factors for the lower CV risk factors in MS patients. Future studies should examine whether the chronic use of many pharmacological agents influence CV risk factors in MS patients.

 

For more details, please visit: http://www.eurekaselect.com/node/107982/article

EDITORS CHOICE ARTICLE – PARP Inhibitors in Ovarian Cancer

Journal Name: Recent Patents on Anti-Cancer Drug Discovery 

Author(s): Gloria Mittica, Eleonora Ghisoni, Gaia Giannone, Sofia Genta, Massimo Aglietta, Anna Sapino, Giorgio Valabrega*.

 

 

Abstract:

Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.

Objectives: The study aimed to highlight the mechanism of action, pharmacokinetics, clinical activity, indications and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, the 5 most relevant PARPis.

Methods: We performed a review on Pubmed using ‘ovarian cancer’ and the name of each PARPi (PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The same search was performed on “clinicaltrial.gov” to identify ongoing clinical trials and on “google. com/patents” and “uspto.gov” for recent patents exploring PARPIs in ovarian cancer.

Results: Olaparib, Niraparib and Rucaparib are already approved for the treatment of recurrent EOC and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, but currently under investigation in early phase trials. Several studies are evaluating PARPis in monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-sensitive and resistant disease).

Conclusion: PARPis are valuable options in patients with recurrent ovarian cancer with promising activity in different stages of this disease. Further studies are required to better define optimal clinical settings, predictors of response beyond BRCA mutations and strategies to overcome secondary resistance of PARPis therapy in EOC.

 

For more details, please visit: http://www.eurekaselect.com/160235/article

BENTHAM SCIENCE FREE TRIAL IN University of Tehran (Free Trial Ends on December 25, 2018)

 

University of Tehran , also known as Tehran University and UT, is Iran’s oldest modern university. It is also one of the most prestigious universities in the Middle East. Based on its historical, socio-cultural, and political pedigree, as well as its research and teaching profile, UT has been nicknamed “The mother university of Iran” and is the symbol of higher education in Iran. It is always ranked as one of the best universities in the Middle East in national and international rankings and one of the best engineering educational programs in the world. The university offers 111 bachelor’s degree programs, 177 master’s degree programs, and 156 Ph.D. programs. Many of the departments were absorbed into the University of Tehran from the Dar al-Funun established in 1851 and the Tehran School of Political Sciences established in 1899.

 

free-trial2

BENTHAM SCIENCE FREE TRIAL IN Beijing University of Chemical Technology (Free Trial Ends on December 26, 2018)

 

Beijing University of Chemical Technology (BUCT) is a high-level university that aims to develop chemical talent at the cutting-edge of science and technology. The university was established in 1958 and formerly known as the Beijing Institute of Chemical Technology. As a national key university directly affiliated to the Ministry of Education of the People’s Republic of China, and as one of the Project 211 universities and 985 Project Innovation Platforms, BUCT has responsibilities for basic and applied scientific research; original, high-tech development; and the training of high-level, innovative talent.

 

free-trial2